PD L1 News and Research

RSS

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

20 Apr 2015

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences today announced the presentation of a study that found drugs targeting specific pathways may have potentially significant benefit in a select subset of patients with uterine cancer. The study results were highlighted today in an oral presentation in a Plenary Session at the Society of Gynecologic Oncology 2015 Annual Meeting on Women's Cancer in Chicago, Ill.

30 Mar 2015

Caris Life Sciences announces record-setting revenue for 2014

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced select year-end financial and operational results for 2014, which include record-setting revenue and continued case volume growth for its panomic, comprehensive tumor profiling service, Caris Molecular Intelligence.

18 Feb 2015

PD-L1 expression tied to favourable prognosis in SCLC

Programmed death-ligand 1 is expressed by around 70% of small-cell lung cancers and is associated with favourable patient outcomes, Japanese researchers report.

10 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology in San Francisco.

7 Dec 2014

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments.

7 Dec 2014

Oncologists examine efficacy of rose bengal against cancer

Rose Bengal has been around for decades starting as a way to dye wool. Originally used in medicine as a stain for ophthalmologists, it has a solid safety record going back to the 1930s. Recently, oncologists have examined its efficacy against cancer, specifically melanoma.

4 Dec 2014

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study led by researchers at Dana-Farber Cancer Institute and the Yale University School of Medicine.

28 Nov 2014

Immune-suppressing protein may predict how patients respond to treatment

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

27 Nov 2014

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.

26 Nov 2014

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.

24 Nov 2014

Protein complex plays key role in detecting tumor cells, promotes anti-tumor response

A recently discovered protein complex known as STING plays a crucial role in detecting the presence of tumor cells and promoting an aggressive anti-tumor response by the body's innate immune system, according to two separate studies published in the Nov. 20 issue of the journal Immunity.

21 Nov 2014

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.

28 Aug 2014

Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody.

25 Aug 2014

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1).

29 Jul 2014